Recent Updates
Recently added Catalysts
PDEX

Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2017

Key Takeaway: Contact: Richard L. Van Kirk, Chief Executive Officer PRO-DEX, INC. ANNOUNCES FISCAL 2017 FIRST IRVINE, CA, November 10, 2016 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2017 first quarter ended September 30, Net sales for the three mon

Full Press Release Details

Contact: Richard L. Van Kirk,
Chief Executive Officer
PRO-DEX, INC. ANNOUNCES FISCAL 2017 FIRST
IRVINE, CA, November
10, 2016 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2017 first quarter ended September 30,
Net sales for the three
months ended September 30, 2016 totaled $5.4 million, an increase of 32% from $4.1 million for the three months ended September
30, 2015. The increase in revenue is due to expansion of our medical device customer base and is primarily driven by the production
ramp of our largest customer's unique surgical hand piece designed to be used for orthopedic surgical applications. Revenue
from this product totaled $2.2 million and $1.1 million for the three months ended September 30, 2016 and 2015, respectively.
Gross profit for the three
months ended September 30, 2016 increased $550,000, or 52%, to $1.6 million, compared to $1.1 million for the year-ago period,
primarily due to the increase in sales, allowing us to better absorb our overhead costs, as well as a decrease in product costs
as we have gained efficiencies in our manufacturing and assembly operations. As a result, gross margin has improved by 4 percentage
points to 30% during the three months ended September 30, 2016 compared to 26% during the corresponding year-ago period.
Operating expenses (which
include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2016 increased
12% to $1.3 million from $1.2 in the prior year's corresponding quarter, reflecting primarily the impairment of intangible
assets of $113,000 relating to the Huber Precision business acquisition.
Net income for the quarter
ended September 30, 2016 was $286,000 or $.07 per share compared to a net loss of $125,000 for the quarter ended September 30,
2015, or $0.03 per share.
Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with the increase in our
net sales this quarter, the improvement of our product margins, and our continued profitability for four successive quarters. We
continue to focus on cost-reductions related to our newest medical device products and have invested in manufacturing equipment
to increase our operational efficiency."
About Pro-Dex, Inc.:
Pro-Dex, Inc., with operations
in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments
used primarily in the orthopedic, spine, maxocranial facial and dental markets. Its OMS division designs and manufactures
embedded motion control systems serving the medical, factory automation, semi-conductor and scientific research markets. Its Fineline
Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex's products are found in hospitals, dental
offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world.
Pro-Dex also provides quality
and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services Division.
For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning
the Company's plans, growth and strategies may include forward-looking statements' within the context of the federal securities
laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations,
beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws.
The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should
refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with
the Securities and Exchange Commission.
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
September 30, 2016 June 30, 2016
ASSETS
Current Assets:
Cash and cash equivalents $ 2,168 $ 2,294
Accounts receivable, net of allowance for doubtful accounts of $15 and $20, respectively 1,542 1,469
Due from factor 2,119 1,419
Deferred costs 493 238
Other current receivables 19 91
Inventory 3,370 3,573
Prepaid expenses 107 134
Total current assets 9,818 9,218
Equipment and leasehold improvements, net 1,583 1,286
Goodwill 112 112
Intangibles, net 336 451
Other assets 80 80
Total assets $ 11,929 $ 11,147
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 1,184 $ 841
Accrued expenses 1,094 1,076
Deferred revenue 319 212
Notes payable 26 26
Income taxes payable - 1
Capital lease obligations 30 -
Total current liabilities 2,653 2,156
Deferred rent, net of current portion 45 68
Notes and capital leases payable, net of current portion 105 46
Total non-current liabilities 150 114
Total liabilities 2,803 2,270
Shareholders' equity:
Common shares; no par value; 50,000,000 shares authorized; 4,063,837 and 4,052,987 shares issued and outstanding at September 30, 2016 and June 30, 2016, respectively 17,951 17,988
Accumulated deficit (8,825 ) (9,111 )
Total shareholders' equity 9,126 8,877
Total liabilities and shareholders' equity $ 11,929 $ 11,147
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share
Three Months Ended September 30,
2016 2015
Net sales $ 5,412 $ 4,097
Cost of sales 3,804 3,039
Gross profit 1,608 1,058
Operating expenses:
Selling expenses 162 214
General and administrative expenses 564 534
Impairment of intangible assets 113 -
Research and development costs 476 429
Total operating expenses 1,315 1,177
Operating income (loss) 293 (119 )
Other income (expense):
Interest and miscellaneous income 3 -
Interest expense (3 ) (6 )
Total other income (expense) - (6 )
Income (loss) before income taxes 293 (125 )
Provision for income taxes 7 -
Net income (loss) $ 286 $ (125 )
Basic and diluted income (loss) per share:
Net income (loss) $ 0.07 $ (0.03 )
Weighted average common shares outstanding:
Basic 4,062,475 4,140,751
Diluted 4,103,459 4,140,751
Common shares outstanding 4,063,837 4,141,504
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH
Three Months Ended September 30,
2016 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 286 $ (125 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization 139 169
Share-based compensation 2 3
Impairment of intangible assets 113 -
Gain on disposal of equipment (3 ) -
Allowance for doubtful accounts (5 ) 4
Changes in operating assets and liabilities:
Accounts receivable, due from factor and other receivables (696 ) 118
Deferred costs (255 ) (241 )
Inventory 203 59
Prepaid expenses and other assets 27 (36 )
Accounts payable, accrued expenses and deferred rent 338 (618 )
Deferred revenue 107 26
Income taxes payable (1 ) -
Net cash provided by (used in) operating activities 255 (641 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment (316 ) -
Increase in notes receivable - (57 )
Increase in intangibles (13 ) (1 )
Proceeds from disposal of equipment 3 -
Net cash used in investing activities (326 ) (58 )
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital lease and notes payable (16 ) (9 )
Borrowings from Summit Loan 400 300
Repayments on Summit Loan (400 ) (300 )
Proceeds from note payable - 500
Proceeds from ESPP Contributions 10 4
Repurchases of common stock (49 ) -
Net cash provided by (used in) financing activities (55 ) 495
Net decrease in cash and cash equivalents (126 ) (204 )
Cash and cash equivalents, beginning of period 2,294 697
Cash and cash equivalents, end of period $ 2,168 $ 493
Last updated: Nov 10, 2016